1. Home
  2. BLLN vs FOLD Comparison

BLLN vs FOLD Comparison

Compare BLLN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$96.06

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.49

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
FOLD
Founded
2016
2002
Country
United States
United States
Employees
713
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.5B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
BLLN
FOLD
Price
$96.06
$14.49
Analyst Decision
Buy
Buy
Analyst Count
7
9
Target Price
$126.71
$27.25
AVG Volume (30 Days)
771.8K
2.5M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$46.29
$20.50
Revenue Next Year
$30.14
$18.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.96
$5.66
52 Week High
$138.70
$14.50

Technical Indicators

Market Signals
Indicator
BLLN
FOLD
Relative Strength Index (RSI) 55.60 74.18
Support Level $79.07 $14.21
Resistance Level $97.36 N/A
Average True Range (ATR) 7.92 0.02
MACD 0.95 -0.00
Stochastic Oscillator 58.11 100.00

Price Performance

Historical Comparison
BLLN
FOLD

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: